SAN FRANCISCO and SUZHOU, China, June 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and ...

Akeso, Inc. (9926.HK)The approval for cadonilimab's use in combination with chemotherapy (with or without bevacizumab) in first-line cervical cancer is based on the clinical data from the Phase ...

REHOVOT, Israel, June 04, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek ...

SAN DIEGO, CA, USA I June 03, 2025 I Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced initiation of a Phase 1 ...

Purple Biotech Announces Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Platform Provided by GlobeNewswire Jun 4, 2025, 11:00:00 AM ...

Akeso's PD-1/CTLA-4 Bispecific Antibody Cadonilimab Approved for First-Line Treatment of Cervical Cancer in All-Comer Populations--Third Approved Indication for Cadonilimab By Akeso, Inc. Jun 4, 2025 ...

SAN FRANCISCO and SUZHOU, China, June 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

The initial data from the Phase I trial (NCT05652335) of JNJ-5322 shows that the trispecific antibody led to a 100% overall response rate (ORR) in 27 patients who were naïve to anti-BCMA/-GPRC5D ...

BioNTech’s BNT327, a next-generation bispecific antibody candidate targeting PD-L1 and VEGF-A, is currently being evaluated in multiple ongoing trials with more than 1,000 patients treated to date, ...

PD-1/IL-2 α-bias bispecific antibody fusion protein IBI363 monotherapy and combined with bevacizumab in participants with advanced colorectal cancer: results from Phase 1 studies Two Phase 1 studies ...

Bristol Myers Squibb said Monday it will pay the German firm BioNTech billions of dollars to split rights for an experimental cancer drug called BNT327, which works on both PD-L1, the target of ...